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Abstract: Staphylococcus aureus is a commensal and frequent colonizer of the upper respiratory tract.
When mechanical ventilation disrupts natural defenses, S. aureus is frequently isolated from the lower
airways, but distinguishing between colonization and infection is difficult. The objectives of this
study were (1) to investigate the bacterial genome sequence in consecutive isolates in order to identify
changes related to the pathological adaptation to the lower respiratory tract and (2) to explore the
relationship between specific phenotypic and genotypic features with the patient’s study group,
persistence of the clinical isolate and clinical outcome. A set of 94 clinical isolates were selected and
corresponded to 34 patients that were classified as having pneumonia (10), tracheobronchitis (11)
and bronchial colonization (13). Clinical strains were phenotypically characterized by conventional
identification and susceptibility testing methods. Isolates underwent whole genome sequencing
using Illumina HiSeq4000. Genotypic characterization was performed with an in-house pipeline
(BacterialTyper). Genomic variation arising within-host was determined by comparing mapped
sequences and de novo assemblies. Virulence factors important in staphylococcal colonization and
infection were characterized using previously established functional assays. (1) Toxin production
was assessed using a THP-1 cytotoxicity assay, which reports on the gross cytotoxicity of individual
isolates. In addition, we investigated the expression of the major virulence factor, alpha-toxin
(Hla) by Western blot. (2) Adhesion to the important extracellular matrix molecule, fibronectin,
was determined using a standardized microtitre plate assay. Finally, invasion experiments using
THP-1 and A539 cell lines and selected clinical strains were also performed. Repeated isolation
of S. aureus from endotracheal aspirate usually reflects persistence of the same strain. Within-host
variation is detectable in this setting, but it shows no evidence of pathological adaptation related to
virulence, resistance or niche adaptations. Cytotoxicity was variable among isolates with 14 strains
showing no cytotoxicity, with these latter presenting an unaltered Fn binding capacity. No changes
on cytotoxicity were reported when comparing study groups. Fn binding capacity was reported
for almost all strains, with the exception of two strains that presented the lowest values. Strains
isolated from patients with pneumonia presented a lower capacity of adhesion in comparison to
those isolated during tracheobronchitis (p = 0.002). Hla was detected in 71 strains (75.5%), with most
of the producer strains in pneumonia and bronchial colonization group (p = 0.06). In our cohort,
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Hla expression (presence or absence) in sequential isolates was usually preserved (70%) although in
seven cases the expression varied over time. No relationship was found between low cytotoxicity
and intracellular persistence in invasion experiments. In our study population, persistent S. aureus
isolation from airways in ventilated patients does not reflect pathological adaptation. There is an
important diversity of sequence types. Cytotoxicity is variable among strains, but no association
with study groups was found, whereas isolates from patients with pneumonia had lower adhesion
capability. Favorable clinical outcome correlated with increased bacterial adhesion in vitro. Most of
the strains isolated from the lower airways were Hla producers and no correlation with an adverse
outcome was reported. The identification of microbial factors that contribute to virulence is relevant
to optimize patient management during lower respiratory tract infections.
Keywords: Staphylococcus aureus; mechanical ventilation; pneumonia; toxicity; adhesion; persistence
Key Contribution: The identification of microbial factors that contribute to virulence is relevant to
optimize patient management during lower respiratory tract infections.
1. Introduction
Staphylococcus aureus is an important human pathogen in both community and hospital
settings. Infections can involve any organ system and can range from asymptomatic
colonization to virulent forms of septicemia reflecting its versatility to survive in diverse
human niches [1–3]. Associations between S. aureus colonization and staphylococcal disease
have been demonstrated. Lungs represent the major site of infection in the intensive care
unit (ICU) and S. aureus is one of the most frequent pathogens identified [4], particularly
within the first week of mechanical ventilation (MV). Studies of prevalence are based on
positive cultures from respiratory samples. However, even when clinicians are confident
S. aureus has been isolated from respiratory sites, the clinical significance of this remains
unclear [5]. Clinicians frequently face the dilemma of distinguishing between microbes
colonizing the upper respiratory tract or actively causing airway and/or parenchymal
infection [6]. In a recent prospective international study involving 1933 ICU patients from
30 European ICUs, S. aureus ICU pneumonia incidence was 4.9 per 1000 ICU patient-days
for patients on MV at ICU admission (or shortly thereafter). Patients colonized with
S. aureus at the time of ICU admission had an almost four-fold higher risk of developing
S. aureus ICU pneumonia and colonization status was the only independent risk factor [7].
S. aureus has been reported to be particularly difficult to eradicate from the respiratory
tract in some situations [8]. In a previous study, we showed persistent isolation despite
antimicrobial treatment adjusted to susceptibility testing was frequent, even in cases with
isolation of methicillin susceptible isolates with no impact on clinical outcome [9]. The
repeated and consecutive isolation of S. aureus in the lower respiratory tract suggests that
the microorganism can survive in this particular niche. Indeed in patients with chronic
respiratory diseases such as cystic fibrosis, this mechanism has been widely reported and
investigated [10,11]. However, its impact during acute lower respiratory tract infection
has not been extensively investigated. Experimental in-vitro approaches characterizing
this persistence mechanism using non-phagocytic and phagocytic cell lines [12], including
alveolar macrophages, which represent the main components of the first line of defense
during lung infections have been developed [13].
S. aureus has multiple virulence factors, including surface proteins and secreted toxins
whose expression relies on a complex network of regulatory systems [14–16]. Fibronectin
binding proteins (FnBPs) are members of the microbial surface components recognizing
adhesive matrix molecules (MSCRAMMs) that have been implicated in the pathogenesis of
staphylococcal infections. S. aureus has two FnBPs, FnBPA and FnBPB, both of which play
a critical role in surface attachment and adhesion to multiple host cells and tissues [16],
including adherence to fibronectin coated surfaces [17,18]. Toxicity has also a significant role
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in the virulence of S. aureus [15]. The ability of pore forming toxins [19], such as leukotoxins
and alpha toxin [20] to lyse host cells causes local tissue damage, triggers inflammatory
response and can facilitate bloodstream dissemination. A special focus has been placed on
the role of alpha toxin during staphylococcal pneumonia, and prophylactic and therapeutic
strategies based on the use of monoclonal antibodies targeting virulence factors are under
investigation [21,22]. Improving our understanding of the role for virulence factors in
S. aureus pathogenesis is a critical step for successful vaccine development [23].
In the present study we conducted an extensive genotypic and phenotypic characteri-
zation of clinical strains of S. aureus isolated from patients during mechanical ventilation.
The objectives were (1) to investigate bacterial genomes in sequential isolates in order to
identify changes related to the pathological adaptation to the lower respiratory tract and
(2) to explore the relationship between specific phenotypic and genotypic features with the
patient’s study group, persistence of the clinical isolate and clinical outcome.
2. Results
2.1. Patients and Strains
The collection of bacterial isolates consisted of 94 strains, corresponding to 34 patients
that were classified as follows: pneumonia (10 patients), tracheobronchitis (11 patients) and
bronchial colonization (13 patients) (Table 1). Among the 34 cases, 24 were considered as
persistent isolation in respiratory sample (>7 days). For 12 patients, S. aureus was isolated
in ETA but also in other clinical samples (blood culture (BC), pleural effusion, nasal swab
and/or central venous catheter) during the same episode. See additional details and the
main characteristics of the study population, including the number of isolates per patient
in Table 1.
Sixty-seven (71.3%) isolates were methicillin susceptible (MSSA) and 27 (28.7%) were
methicillin resistant (MRSA). All strains were vancomycin, teicoplanin and daptomycin
susceptible, except for one MRSA isolate that was daptomycin resistant.
2.2. Genomic Characterization
Results of the genomic characterization using BacterialTyper (https://github.com/
HCGB-IGTP/BacterialTyper) (v0.4.2, accessed on 1 August 2020) are available in Figure 1
and Supplementary Table S3. Clustering results, multilocus sequence type (MLST), spa
typing, number of mobile genetic elements (phages and genomic islands) and the resistance
and toxin/virulence factor genes selected are shown. See details and additional information
in Supplementary Table S3.
Isolates belonged to 16 MLST. The most dominant MLST types (considering the
94 isolates) identified were ST146 (17.8%), ST125 (12%), ST15 (9.5%), ST 8 (8.3%) and ST 22
(8.3%). Seven strains could not be assigned to any known sequence type (ST) (allele not
described for glpF (4 isolates), for pta (2 isolates) and for yqiL (1 isolate)). Interestingly, for
three cases (ID 15, 146 and 181) more than one ST was identified per patient. For ID 15, ST
8 and ST 5 were detected; ID 146, ST 12 and ST15; and ID 181, ST7 and ST30. For ID146 and
181, ST were clustered in two different clinical episodes, while for the remaining one (ID15),
both ST were simultaneously detected during the same episode. For the following ID cases
(ID 36, 37, 41, 59, 115, 126 and 193), although strains presented the same ST (considering
each patient individually), the gene profile displayed some differences (presence/absence
of a selected gene) (Figure 1).
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Table 1. Description of study population: study group according to clinical criteria, number of isolates, days between isolation, clinical samples collected, persistent isolation in respiratory
sample and clinical outcome.
Patient ID Study Group Number of Isolates Clinical Samples a Persistent Isolation b (Days)
Respiratory Complications
and/or Mortality Related
4 Pneumonia 2 Nasal swab, blood culture Yes (54) c Yes
9 Bronchial colonization 2 Tracheal aspirate No No
11 Tracheobronchitis 2 Tracheal aspirate, blood culture No No
15 Tracheobronchitis 3 Tracheal aspirate Yes (11) No
17 Bronchial colonization 2 Tracheal aspirate Yes (7) No
18 Bronchial colonization 2 Tracheal aspirate, blood culture No No
28 Tracheobronchitis 2 Tracheal aspirate Yes (8) No
32 Bronchial colonization 3 Nasal swab, sputum, tracheal aspirate No No
36 Pneumonia 2 Tracheal aspirate, blood culture No Yes
37 Bronchial colonization 4 Tracheal aspirate (3), nasal swab Yes (52) No
41 Bronchial colonization 3 Tracheal aspirate (2), sputum Yes (57) No
46 Tracheobronchitis 2 Tracheal aspirate (2) Yes (8) No
48 Bronchial colonization 2 Tracheal aspirate (2) Yes (15) No
50 Tracheobronchitis 2 Tracheal aspirate (2) Yes (9) No
52 Bronchial colonization 1 Tracheal aspirate No No
54 Tracheobronchitis 2 Tracheal aspirate (2) Yes (14) No
59 Pneumonia 3 Tracheal aspirate (3) Yes (62) No
67 Pneumonia 2 Tracheal aspirate, blood culture No Yes
83 Bronchial colonization 2 Tracheal aspirate, blood culture Yes (73) No
103 Bronchial colonization 6 Sputum (6) Yes (524) No
112 Tracheobronchitis 2 Tracheal aspirate, blood culture No No
115 Pneumonia 7
Tracheal aspirate (2), blood culture,
sputum (2), pleural effusion,
protected brush
Yes (74) Yes
116 Pneumonia 2 Tracheal aspirate No Yes
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Table 1. Cont.
Patient ID Study Group Number of Isolates Clinical Samples a Persistent Isolation b (Days)
Respiratory Complications
and/or Mortality Related
121 Pneumonia 3 Tracheal aspirate Yes (8) No
124 Tracheobronchitis 2 Tracheal aspirate Yes (21) No
126 Pneumonia 4 Tracheal aspirate Yes (28) Yes
133 Pneumonia 2 Tracheal aspirate Yes (11) No
144 Tracheobronchitis 3 Tracheal aspirate Yes (12) No
146 Tracheobronchitis 5 Tracheal aspirate Yes (176) No
181 Tracheobronchitis 2 Tracheal aspirate Yes (92) No
184 Bronchial colonization 4 Tracheal aspirate Yes (15) No
185 Bronchial colonization 4 Tracheal aspirate (3),nasal swab Yes (10) No





193 Pneumonia 2 Tracheal aspirate No Yes
a, Clinical specimens, the numbers correspond to the total count; b, persistent isolation of S. aureus in lower respiratory tract samples, the numbers corresponds to the days of persistence. c, Only nasal swab and
blood culture isolates were frozen and available for further characterization.
Toxins 2021, 13, 122 6 of 23
Toxins 2021, 13, x FOR PEER REVIEW 5 of 22 
 
 
Finally, three isolates (from the same patient, ID 103) were identified using Bacteri-
alTyper as Staphylococcus pseudointermedius. Additionally, neither MLST nor spa typifica-
tion resulted positive for these samples. Reanalysis of these samples using MALDI-TOF 
(Bruker) confirmed them as S. pseudointermedius. 
 
Figure 1. Summary of genomic characterization results for all samples analyzed in this study. From left to right: (1) Se-
quence similarity clustering tree; (2) bacterial isolate numeric identifiers (culture number in Supplementary Table S2) Red 
color corresponds to samples containing Enterococcus faecalis DNA; (3) patient, individual patient numeric identifiers (ID 
patient in Supplementary Table S2), color coded by status (red, no change; green, change) diverging sequence type (ST) 
assignment between isolates from the lower respiratory tract (tracheal aspirate and sputum) of the same patient; patients 
15, 146 and 181, are graphically labeled. (4) Origin, isolation source with the following color code: dark blue, lower res-
piratory tract (LRT) including tracheal aspirate, pleural effusion, protected brush specimen and sputum; light blue, nasal 
swab and light green, blood culture (including one central venous catheter); (5) order, corresponding to order of isolation 
for serial LRT samples and (6) ST (strain type) multilocus sequence typing (MLST) assignment results. Asterisks (*) in-
dicate ST could not be assigned. (7) Spa typing protein results. Code corresponds to Ridom Spa Server nomenclature 
(https://spaserver2.ridom.de/, accessed on 1 August 2020). Asterisks (*) indicate Spa type could not be assigned; hash (#) 
corresponds to an unknown spa type, see Supplementary Table S2 for details. (8) Genotyping results for several genes of 
interest, color coded by presence (cyan), absence (salmon) or ambiguous (green). The first block corresponds to some re-
sistance and virulence genes (mecA, fnbA, fnbB, pvl, chp, scn and sak) and the following block contains hemolysin en-
coding genes (hla, hlb and hld), including Western blot (WB) results for Hla (Hla WB). (9) MGE, mobile genetic elements. 
Grey scale quantitative heatmap showing the number of phage insertions (Phage) and genomic islands (GI) detected for 
each sample. Data from 91 isolates and 34 individuals is shown. 
Figure 1. f eno ic characterization results for all samples analyzed in thi study. From left to right: (1)
Sequence similarity clustering tree; (2) bacterial isolate numeric identifiers (culture number in Supplementary Table S2)
Red color corresponds to samples containing Enterococcus faecalis DNA; (3) patient, individual patient numeric identifiers
(ID patient in Supplementary Table S2), color coded by status (red, no change; green, change) diverging sequence type
(ST) assignment between isolates from the lower respiratory tract (tracheal aspirate and sputum) of the same patient;
patients 15, 146 and 181, are graphically labeled. (4) Origin, isolation source with the following color code: dark blue,
lower respiratory tract (LRT) including tracheal aspirate, pleural effusion, protected brush specimen and sputum; light
blue, nasal swab and light green, blood culture (including one central venous catheter); (5) order, corresponding to order of
isolation for serial LRT samples and (6) ST (strai type) multilocus sequence typing (MLST) assignment results. Asterisks (*)
indicate ST could not be assigned. (7) Spa typin protein results. Code corresponds o Rid m Spa Server nomenclature
(https://spaserver2.ridom.de/, accessed on 1 August 2020). Asterisks (*) indicate Spa e could not be assigned; hash
(#) corresponds to an unknown spa type, see Supplementary Table S2 for details. (8) Genotyping results for several genes
of interest, color coded by presence (cyan), absence (salmon) or ambiguous (green). The first block corresponds to some
resistance and virulence genes (mecA, fnbA, fnbB, pvl, chp, scn and sak) and the following block contains hemolysin encoding
genes (hla, hlb and hld), including Western blot (WB) results for Hla (Hla WB). (9) MGE, mobile genetic elements. Grey scale
quantitative heatmap showing the number of phage insertions (Phage) and genomic islands (GI) detected for each sample.
Data from 91 isolates and 34 individuals is shown.
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A total of 29 different spa types were identified following the Ridom Spa Server
nomenclature (https://spaserver2.ridom.de/, accessed on 1 August 2020). Spatypes t002
(20.21%), t067 (10.63%) and t008 (6.38%) respectively, were the most common repeat types
identified. Other repeat types identified were always under 5% frequencies. One spa repeat,
which was found in two isolates from a single patient, corresponded to an unknown spa
type (26–23–13–23–36–16–28).
For two strains (patient ID 112 and 115) (culture numbers 17919 and 11912), the
pipeline identified the presence of DNA from Enterococcus faecalis, based on assembly size,
quality control and strain identification. For one of the samples, blood culture was positive
for both microorganisms. For the other sample that was a pleural effusion culture, it might
correspond to a cross contamination.
Finally, three isolates (from the same patient, ID 103) were identified using Bacterial-
Typer as Staphylococcus pseudointermedius. Additionally, neither MLST nor spa typification
resulted positive for these samples. Reanalysis of these samples using MALDI-TOF (Bruker)
confirmed them as S. pseudointermedius.
2.3. Within-Host Variation
For this analysis, we selected 73 clinical strains, corresponding to 25 patients with
between 2 and 6 isolates from the lower respiratory tract. In 23 out of 25 individuals,
2 or more sequential isolates were closely related. In 21 out of 25 patients, all isolates
from the same patient were closely related, with strain replacement seen in the remaining
four individuals (Table 2). Maximum likelihood trees of the populations found from each
individual are shown in Figure 2. Related isolates were highly similar: in 5/23, no genetic
variation was detected, with 18/23 showing at least one genetic variant. Up to 31 within-
host variants were detected (median 3 variants, IQR 1–8) with a total of 134 variants
identified (Supplementary Table S4). The majority of variants were non-synonymous or
protein truncating. No variations were identified in the accessory gene regulator locus or
in any cell wall anchored proteins. Gene set enrichment analysis showed no clustering of
variants by gene, in any sets of genes with a known shared ontology or within sets of genes
with shared regulation.
For the evaluation of cytotoxicity and adhesion capacity only the first isolate from ETA
sample was considered, as within-host analysis results showed that repeated isolation of
S. aureus from ETA frequently reflected the persistence of the same strain. Strains isolated
from the other anatomical locations were also included. Cytotoxicity and Fn adhesion
results for the 48 tested strains are shown in Supplementary Figure S1.
2.4. THP-1 Cytotoxicity
Cytotoxicity levels were variable among isolates and ranged between 1% and 60%
(Figure 3). For USA300 strain, the cytotoxicity value was 50%. Fourteen isolates showed no
cytotoxicity. These corresponded to nine patients (Patient ID 11, 50, 67, 83, 103, 112, 115,
144 and 181), 5 were diagnosed as tracheobronchitis, 2 as pneumonia and 2 as bronchial
colonized. Isolates belonged to seven different ST; 10 were alphatoxin producers and
4 non producers and one was pvl positive. Two patients had an unfavorable outcome.
Globally, no statistical differences were reported according to the study group, persistence
nor clinical outcome (Figure 3).
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Table 2. Number of within-host variations identified when comparing isolates from patients included in the study.







9 2 Bronchialcolonization Yes 8 3
15 3 Tracheobronchitis No 5 NA a
17 2 Bronchialcolonization Yes 10 3
28 2 Tracheobronchitis Yes 45 11
32 2 Bronchialcolonization Yes 30 31
41 3 Bronchialcolonization Yes 15 3
46 2 Tracheobronchitis Yes 7 1
48 2 Bronchialcolonization Yes 121 2
50 2 Tracheobronchitis Yes 398 1
54 2 Tracheobronchitis Yes 125 1
59 3 Pneumonia Yes NF 0
103 6 Bronchialcolonization Yes 125 17
116 2 Pneumonia Yes NF 2
121 3 Pneumonia Yes 22 3
124 2 Tracheobronchitis Yes 125 0
126 4 Pneumonia Yes NF 17
133 2 Pneumonia Yes 188 0
144 3 Tracheobronchitis Yes 15 10
146 5 Tracheobronchitis Yes (first 2 of 5) 12 6
181 2 Tracheobronchitis No 7 NA
184 4 Bronchialcolonization Yes 97 15
185 4 Bronchialcolonization Yes (first 3 of 4) 133 6
193 2 Pneumonia Yes 5 0
37 3 Bronchialcolonization Yes 146 0
115 6 Pneumonia Yes 146 4
NA: within-host variants not identified as initial strain replacement by another sequence type; NF: not found; a, This patient had three
isolates. The first isolate was a different ST from the next two.
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2.4. THP-1 Cytotoxicity 
Cytotoxicity levels were variable among isolates and ranged between 1% and 60% 
(Figure 3). For USA300 strain, the cytotoxicity value was 50%. Fourteen isolates showed 
no cytotoxicity. These corresponded to nine patients (Patient ID 11, 50, 67, 83, 103, 112, 
Figure 2. Maximum l kelihood tree of the popula ions found from each ind vidual. Circles represent
distinct genotypes, and are shaded according to the time of isolation of the genotype: white is earliest,
darkest grey is latest. Branches between nodes are shaded according to the types of variants found:
intergenic (grey), synonymous (green), nonsynonymous (orange) and nonsense/premature codon
stop (red). SNPs and indels are represented by solid nd dashed lines, r sp ctively. Small black
circles represent hypothetical intermediate genotypes. Data from 25 individuals is shown.
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Figure 3. Cytotoxicity profile fo the 48 clinical strains. (A). Distribution of cytotoxi ity results.
(B). Cytotoxicity according to the study group considered. (C). Cytotoxicity according to persistent
isolation in the respiratory tract. (D). Cytotoxicity according to the clinical outcome, defined as
development of respiratory complications and/or mortality related. Mann–Whitney U test and
one-way ANOVA test were used. No statistical differences were found.
2.5. Fn Binding Capacity
Adherence was variable among the 48 isolates as shown in Figure 4, alt ough st
of the strains had values between 50% and 80%. Two strains presented the lowest values
(<20%), and both were isolated from the same patient that belonged to the pneumonia group
(Patient ID 4). Both strains were positive for fnbA and fnbB. For wild type strain (8325.4),
adherence corresponded to 100% and the value obtained for 8325.4 ∆fnb (deletion of both
FnBPA and FnBPB) was 54%. Strains isolated from patients with pneumonia presented
a lower capacity of a hesion in comparison to those isolated during tracheobronchitis
(p = 0.004). Regarding persistence, no statistical differences were reported. Adhesion values
reported for isolates from respiratory complications and/or the mortality related group
were significantly lower in comparison to isolates from favorable outcome cases (p = 0.0015).
Regarding the frequency of strains according to the presence of fnb genes, 85 strains were
positive for fnbA and fnbB (90.4%), 6 strains were positive for fnbA/negative for fnbB (6.4%)
and 3 strains were negative for both genes (3.2%). The latter ones corresponded to S.
pseudointermedius isolates. In this case, ambiguous results for the genomic characterization
of fnbA/fnbB genes were due to accumulation of non-synonymous variants or partial
assemblies as a result of misassembles in the repeated regions of these proteins [24].
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2.6. Alpha Toxin Detection by Western Blot
Given the fact that Hla is one of the most studied toxins involved in airway infection,
we were interested in analyzing its expression in the complete set of 94 strains. Eighty-six
isolates (94.5%) had the hla gene present. Globally, Hla expression by western blot (WB)
was detected in 71 isolates (78%). Examples of this WB are shown in Figure 5A. For five
strains, the hla gene was r ported as ambiguous, as it e c ded a truncated form of the
protein (amino acid position 112/319). However, one of these str in (culture number
98934) had a positive WB. Considering one strain per patient (the first one isolated from
the lower respiratory tract), the distribution of Hla results according to the study group is
shown in Figure 5B (p = 0.496). The distribution of Hla results according to the outcome are
shown in Figure 5C (p = 0.999). There was no statistical significance between Hla expression
and cytotoxicity and adhesion values (Figure 5D,E).
Toxins 2021, 13, 122 13 of 23
Toxins 2021, 13, x FOR PEER REVIEW 11 of 22 
 
 
the outcome are shown in Figure 5C (p = 0.999). There was no statistical significance be-
tween Hla expression and cytotoxicity and adhesion values (Figure 5D–E). 
For the analysis of Hla expression in consecutive isolates, we selected 65 clinical 
strains that corresponded to 23 patients classified as persistent isolation. There is one case 
(Patient ID 4) that was considered persistent but isolates available for genotypic and 
phenotypic characterization were a nasal swab and a blood culture. For 16 cases, there 
were no changes in Hla expression: in 12 cases all isolates were Hla positive (Patient ID 9, 
28, 41, 46, 103, 116, 121, 126, 133, 146, 184 and 185) and for 5 cases all isolates were Hla 
negative (Patient ID 17, 32, 50, 124 and 181). For two cases (Patient ID 15 and 54), Hla was 
initially detected but later no expression was reported, and in two cases (Patient ID 48, 59, 
144 and 193), Hla was initially absent but later reported. Overall, Hla expression (pres-
ence or absence) in sequential isolates was usually preserved (72.8%) although in six 
cases the expression varied over time. Among these six cases, in five of them within-host 
analysis showed acquisition of a novel strain over time. 
 
Figure 5. Hla expression. (A). Image with examples of positive (pos) and negative (neg) Hla WB results, including clinical 
isolates and control strains (USA300, NE1354 Tn::hla). (B). Number of isolates (one per patient) according to the study 
group and Hla expression (positive/ negative). (C). Number of isolates (one per patient) according to the clinical outcome 
and Hla expression. (D). Cytotoxicity and (E). Adhesion values according to Hla expression. Mann–Whitney U test and 
Fisher’s exact test were used. No statistical differences were found. 
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results, including clinical isolates and control strains (USA300, NE1354 Tn::hla). (B). Number of
isolates (one per pati nt) according to th study group a d Hla expression (positive/ negative). (C).
Number of is lates (o e per patient) according to the clinica outcome a d Hla expression. (D).
Cytotoxicity and (E). Adhesion values according to Hla expression. Mann–Whitney U test and
Fisher’s exact test were used. No statistical differences were found.
For the analysis of Hla expression in consecutive isolates, we selected 65 clinical strains
that corresponded to 23 patients classified as persistent isolation. There is one case (Patient
ID 4) that was considered persistent but isolates available for genotypic and phenotypic
characterization were a nasal swab and a blood culture. For 16 cases, there were no changes
in Hla expression: in 12 cases all isolates were Hla positive (Patient ID 9, 28, 41, 46, 103,
116, 121, 126, 133, 146, 184 and 185) and for 5 cases all isolates were Hla negative (Patient
ID 17, 32, 50, 124 and 181). For two cases (Patient ID 15 and 54), Hla was initially detected
but later no expression was reported, and in two cases (Patient ID 48, 59, 144 and 193),
Hla was initially absent but later reported. Overall, Hla expression (presence or absence)
in sequential isolates was usually preserved (72.8%) although in six cases the expression
varied over time. Among these six cases, in five of them within-host analysis showed
acquisition of a novel strain over time.
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2.7. Invasion and Persistence Assay
Regarding the murine alveolar macrophage (MH-S) invasion assay, all isolates showed
a similar dynamic, regardless of the clinical group, persistence and cytotoxicity (Figure 6A).
For tree isolates, there was an initial decrease in bacterial counts after the 1 h incubation
with gentamycin and a slight increase in the following 2 h incubation. Bacterial counts
remained constant until 7.5 h post infection (p.i). From that time point a slight decrease was
reported. From 21.5 to 28.5 h p.i, counts remained constant, suggesting a balance between
bacterial killing and intracellular survival. Regarding A549 assay (Figure 6B), bacterial
counts showed that all strains adhered efficiently and are internalized after 2 h, regardless
of the cytotoxicity (addressed by THP-1 cytotoxicity assay). Strains are ordered in the x-axis
according to the cytotoxicity value obtained. Interestingly, there were two strains from the
same patient (ID 137) that reported the highest counts for adhesion time point (26077 and
21564), whereas no counts were detected for the internalization time point.
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Figure 6. Invasion assays in murine alveolar macrophage (MH-S) and A549 cell lines. (A). Time
course analysis for 4 S. aureus clinical isolates in infected MH-S. Log 10 c.f.u./well are the average of
three independent experiments. (B). Adhesion and internalization bacterial counts after infection of
the A549 cell line with selected clinical strains. c.f.u./mL are the average of three independent experi-
ments.
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3. Discussion
S. aureus pathogenesis during bacteremia, endocarditis and skin and soft tissue in-
fections has been extensively evaluated [1]. Genomic signatures in S. aureus of invasive
or persistent infection have been investigated, although with conflicting results [25–27].
S. aureus clinical features in the respiratory tract can range from asymptomatic carriage to
severe invasive disease, demonstrating a switch in virulence regulation [1,28]. Most studies
of pneumonia have focused on assessing differences of outcome between MRSA and MSSA,
because of its importance regarding available antimicrobial options [29,30] and identifying
the potential role of specific virulence factors such as Panton–Valentine leukocidin [31] and
alpha-toxin [32] in an adverse clinical outcome. Although S. aureus persistent isolation
in the lower respiratory tract is distinct from invasive infection, isolates might also be
subjected to the pressures of the immune response, lack of nutrients, coexisting microor-
ganisms and antimicrobials [33]. Thus, access to sequential isolates offers an opportunity
to characterize pathological host adaptation in this anatomical location. In the current
study, we performed an exhaustive genotypic characterization of S. aureus clinical strains
sequentially isolated from patients under mechanical ventilation [9]. Previous studies
of invasive S. aureus infection have demonstrated low within-host diversity in infecting
populations, and changes in regulatory genes, especially the Agr locus, associated with the
development of bacteremia and invasive infections [34–36]. In contrast, while within-host
variation is detectable in our setting, we found no evidence of pathological adaptation
related to virulence, resistance or niche adaptation. There was no observable difference
between the phenotypes of colonization and infection in the degree of diversity observed
within repeated samplings. Colonization and infection of the lower respiratory tract may
involve distinct evolutionary pressures compared with the bloodstream or deep soft tissue.
Clinically, repeated isolation of S. aureus from the lower respiratory tract did not correlate
with worse outcomes compared with patients with only a single S. aureus tracheal aspirate
culture [9]. As it has been previously mentioned, from a clinical perspective, in some cir-
cumstances the diagnosis of respiratory tract infections can be complex [6]. Regarding the
three study groups defined, there is no gold standard for clear distinction, and this may be
a reason for not seeing differences between study groups in terms of within-host variation.
An interesting aspect of our study is that it represents a non-uniform population of
clinically relevant isolates. Cases were retrospectively included on the basis of a S. aureus
positive respiratory specimen culture result and the storage of the clinical isolate at −80 ◦C
for further characterization. Inclusion was not dependent on patients’ criteria and strains
were not collected in the same time points for all patients. Indeed, sequence clustering
and ST among isolates was very heterogeneous (Figure 1), highlighting wide genetic
diversity and thus low patient-to-patient transmission in the ICU. Cytotoxicity displayed
a wide range of values and did not correlate with any of the variables considered (study
group, persistence and clinical outcome), including the expression of alpha toxin. For most
isolates, values were lower than the one found for the reference strain (USA300), suggesting
low toxicity for the respiratory isolates. This low cytotoxicity was found in bronchial
colonization and pneumonia isolates, which could be seen as opposite clinical situations,
suggesting that virulence factors involved in tissue destruction are not the sole or major
determinants of pathogenesis. Low cytotoxicity is considered an adaptation strategy
to facilitate intracellular persistence and chronic infections [37]. With the experimental
approaches performed, this relationship was not demonstrated, although we showed
that S. aureus was able to persist intracellularly in two different human cell lines. It is
important to remind that patients included in our study did not present a chronic infection,
but an acute lower respiratory tract infection, which in some cases lead to persistent
bronchial colonization.
The majority of strains were alpha-toxin positive and only two strains were PVL
positive. One explanation would be that in order to adapt to the lower respiratory tract
S. aureus downregulates agr expression among others [3]. In addition, for medium/long
term survival in the airways, toxin expression would have to be tightly regulated in favor of
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persistence. In a study by Laabei M et al., a higher propensity for low cytotoxicity isolates
to cause bacteremia was reported [38], and this was explained by evolutionary trade-offs
and bacterial fitness. Adherence was also variable among respiratory isolates, reflecting
heterogeneity within the bacterial population. Isolates from pneumonia group displayed
significantly lower values of adhesion in comparison to tracheobronchitis group. Adhesion
was also significantly lower for cases with unfavorable outcome. This is consistent with the
fact that among the 34 clinical cases, 7 presented development of respiratory complications
and/or mortality related. All of them belonged to the pneumonia study group, which
includes those patients with worse outcomes [9]. Adherence to fibronectin did not differ
between isolates with one or two fnb genes, as previously shown [17]. Interestingly,
there were 16 strains that lacked both genes, but still showed Fn adhesion capacity. The
explanation for this result can be that many cell wall anchored proteins show functional
redundancy [16].
Alpha toxin is a relevant virulence factor in S. aureus induced pneumonia [20,28] and
targets multiple host cell types. Alpha toxin expression depends on a complex interplay of
regulatory networks, alternative sigma factors and transcription factors [20] and during
infection its production is also modulated in the presence of phenol-soluble modulin
peptides [39]. It has been proposed that the hla gene evolved together with S. aureus genetic
background [40]. In the same direction, Tabor et al. found that hla was highly conserved
among isolates from the lower respiratory tract [32]. In our study, almost all of the isolates
were positive for the hla gene, and about 75% of them were Hla producers. Particularly for
the pneumonia study group, almost 90% of the isolates were Hla producers, suggesting an
association with this clinical condition. Although the number of patients in our cohort is
low, it provides evidence regarding the role of this virulence factor during lower respiratory
tract infections. Regarding sequential isolates, its expression was usually preserved, with
the exception of a few cases for which the expression varied over time. Most of these cases,
corresponded to the cases identified in within-host analysis as novel strains acquisitions,
different than the index case.
The complex interplay between host (host genetic risk factors, epidemiological char-
acteristics and presence of comorbidities) and microbial genetic determinants (arsenal of
virulence factors and tight gene expression regulation) is not only dependent on the clinical
condition [6,41]. It is important to mention that in-vivo conditions might be different than
in-vitro conditions. It is difficult to assess which growth phase is relevant in terms of toxic-
ity and adhesion during in-vivo disease. However, for the different tests performed in the
current study, bacterial supernatants were prepared, accordingly, at the early exponential
phase for adhesion assays, and at the late exponential to stationary phase of growth for
toxicity and alpha toxin secretion assays. It is widely accepted that growth media can
influence virulence factor secretion [42] and literature supports TSB as one of the more
appropriate to perform phenotypic assays exploring S. aureus pathogenesis.
In summary, our results show that there is a diversity of S. aureus isolates in terms of
CC/ST and virulence/resistance genes profile. Within-host variation is detectable in our
setting, but it shows no evidence of pathological adaptation related to virulence, resistance
or niche adaptation. Cytotoxicity was variable among strains, but no association with study
groups, clinical outcome and persistence was found, whereas isolates from patients with
pneumonia and unfavorable outcome had lower Fn adhesion capability. Most of the strains
were alpha-toxin producers. Hla expression (presence or absence) in sequential isolates
was usually preserved although in a small proportion of the cases, the expression varied
over time. The identification of microbial factors that contribute to virulence is relevant to
optimize patient management during lower respiratory tract infections.
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4. Material and Methods
4.1. Patients and Strains
The study is observational. Patients admitted to ICU over a 2 year period (2012–2013)
and from whom S. aureus was isolated in at least one endotracheal aspirate (ETA) were
selected as described previously [9]. All patients at inclusion were under mechanical
ventilation. Ethical approval was provided by the Institutional Review Board: Comitè
d’Ètica de la Investigació de l’Hospital Germans Trias i Pujol. Sample collection followed
the standard of care and was based on clinical (and radiological when applicable) suspicion
of infection, and not as surveillance culture. No intervention was applied to the collection
timing. Epidemiological, radiological, clinical and microbiological data were recorded.
Adverse clinical outcome included the development of respiratory complications following
definitions from Ferrando et al. [43], including empyema and septic shock and infection-
related mortality. Isolation in ETA was defined persistent when it lasted ≥7 days despite
antimicrobial treatment adjusted to susceptibility profile, and was considered regardless of
the study group. Patients were clustered into pneumonia, tracheobronchitis or bronchial
colonization according to the Clinical Pulmonary Infection Score (CPIS). Pneumonia (CPIS
≥ 6) was considered ventilator associated (VAP) when its onset occurred after ≥48 h of MV.
Ventilator associated tracheobronchitis (VAT) was defined when the following 4 criteria
were present: fever (≥38 ◦C) with no other recognizable cause, purulent secretion, positive
culture of respiratory specimen at significant threshold, (by semiquantitative culture) [44]
and no radiographic signs of new pneumonia [4]. Bronchial colonization was defined as
S. aureus isolation in respiratory sample but at least one of the aforementioned clinical,
microbiological and radiological features absent. Isolates were stored in maintenance freeze
medium (15% glycerol) (Oxoid, TP15731) at −80 ◦C until use.
4.2. Whole Genome Sequencing
S. aureus isolates were grown overnight in 2 mL of tryptic-soy broth (TSB). Overnight
cultures were centrifuged at 5000× g, 5 min and supernatants were discarded. Bacterial
pellet was suspended with enzyme solution (200 µg/mL lysostaphin (AMBI products,
Lawrence, KS, USA); 20 mM Tris·HCl, pH 8.0; 2 mM EDTA; 1.2% Triton X-100) and in-
cubated for 1 h at 37 ◦C. Incubation with 4 µL RNAase A (stock solution 100 mg/mL)
(Qiagen 19101) (Qiagen, Hilden, Germany) was also performed (1 h at 56 ◦C). Genomic
DNA (gDNA) was prepared using DNA mini and Blood mini kit (Qiagen 51304) (Qi-
agen, Hilden, Germany) according to the manufacturer’s instructions. gDNA concen-
tration and integrity was checked with picogreen fluorometry and SYBR-green agarose
gel electrophoresis, respectively. A minimum of 1 µg DNA resuspended in AE buffer
(30 ng/mL) was submitted to the Wellcome Trust Centre for Human Genetics (WTCHG)
(University of Oxford, Oxford, UK) and subjected to genome sequencing on an Illumina
HiSeq4000, with 2 × 150 bp long paired end reads. The whole-genome shotgun project
has been deposited in DDBJ/ENA/GenBank under accession number PRJNA673063. This
project repository includes raw data, sample details and sequencing libraries information
(Supplementary Table S1).
4.3. Genomic Characterization
We generated a genomic characterization for all samples using the in-house pipeline
named BacterialTyper [45] (https://github.com/HCGB-IGTP/BacterialTyper, accessed
on 1 August 2020). It is written in Python with a modular architecture and based on
an open-source software and databases engines. Multiple tasks are performed by each
module that can integrate multiple software packages. For this analysis we used modules
regarding: generation of raw data quality control (FastQC [46] and MultiQC) [47]); assem-
bly (Spades [48]), annotation (prokka [49]) and quality control (BUSCO [50]); multilocus
sequence typing (MLST) (MLSTar [51]) and staphylococcal protein A (spa) characterization
(spaTyper [50,52]); bacterial strain identification (kma [53]); analysis of putative pathogenic-
ity islands (islandpath [54]) and phage insertions regions (Phispy [55]); sequence similarity
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clustering (mash [56,57]); generation of a virulence and resistance profile (ARIBA [58])
based on external databases such as the Virulence Factor Database (VFDB [59]) and Com-
prehensive Antibiotic Resistance Database (CARD [60]). For this analysis results might be
either presence, absence or ambiguous. We set as ambiguous any result that is not clearly
determined to be present/absent by ARIBA. We would include in this category partial
genes (<80% assembly length) or these genes present but not producing the phenotype
(e.g., gene is truncated or contains frameshift variants, etc.).
Genomic characterization results were summarized using R packages treeio [61],
ggtree and ggtreeExtra [62]. We included: sequence similarity clustering tree information;
selected genes from the resistance and virulence profiles; MLST, spa typing results and
patient or phenotypic information associated for each sample analyzed.
4.4. Within-Host Variation Analysis
For each sample, reads were mapped to a reference strain (MRSA252) [63] using
Stampy v 1.0.22 [64]. Repetitive regions identified using BLAST [65] were masked prior to
variant calling, and bases at each position were called using previously described quality
filters [63–65]. Reads were assembled de novo into contigs using Velvet v1.0.18 [66] and
using Velvet Optimiser v2.1.7 [66] to choose kmer lengths for each assembly. MLST was
determined by identifying MLST alleles in assemblies with BLAST, and comparison to an
online database at http://saureus.mlst.net (accessed on 1 August 2020). For isolates of
the same sequence type (ST) obtained from a single individual, we identified all variants
within the host population using Cortex [67] to identify SNPs and indels. SNP distances
were used for comparison between groups. Variants were annotated for their location and
predicted effect on protein by comparison to reference genomes using BLAST. Gene set
enrichment analysis was performed as previously described [35], testing for genes (and sets
of genes with a shared ontology or shared regulatory control) with a higher than expected
number of variants.
4.5. Phenotypic Characterization
Clinical strains were phenotypically characterized by conventional identification
and susceptibility testing methods, interpreted according to the Clinical and Labora-
tory Standards Institute. Antimicrobials tested were: penicillin, oxacillin, erythromycin,
clindamycin, cefoxitin, cotrimoxazole (trimethroprim/sulfamethoxazole), gentamicin, ri-
fampicin, ciprofloxacin, vancomycin and mupirocin. In addition, minimal inhibitory
concentration (MIC) for vancomycin, daptomycin and teicoplanin were determined with
UMIC commercial assay (Biocentric, Hain Lifescience, Germany). Reference strains used
were Newman, USA300, 8325.4, 8325.4 ∆fnb and NE1354 Tn::hla WB.
4.6. THP-1 Cytotoxicity Assay
To investigate the gross cytolytic activity of the isolates collection, the toxicity of
bacterial supernatants to the immortalized monocyte–macrophage THP-1 cell line was
evaluated using an adapted protocol already published [36,68]. S. aureus isolates were
grown overnight in 1.5 mL of TSB during 15–18 h at 37 ◦C, 180 rpm. Overnight cultures
were centrifuged at 4000 rpm, 10 min and supernatants filtered through 0.2-micron filter.
The monocyte macrophage THP-1 cell line was grown in RPMI-1640, supplemented with
10% heat-inactivated fetal bovine serum, Hepes 10 mM and antibiotics/antifungals at
37 ◦C in a humidified incubator with 5% CO2. Cells were routinely viewed microscopically
every 48–60 h and harvested by centrifugation at 1200 rpm for 5 min at room temperature
and resuspended to a final density of 2–4 × 105 cells/mL. To monitor S. aureus toxicity,
45 µL of cells (1.7 × 105 cells/mL) were incubated with 45 µL of bacterial supernatant and
incubated for 12 min at 37 ◦C with 5% CO2. Cell viability was quantified using Presto
Blue (Invitrogen) according to the manufacturer’s instructions. Experiments were done in
triplicate and repeated three times. Error bars indicate ±95% confidence interval.
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4.7. Fibronectin Binding Assay
To investigate fibronectin binding protein adherence to human fibronectin, an adapted
protocol previously published was used [18]. S. aureus isolates were grown overnight in
5 mL of tryptic soy broth (TSB) during 15–18 h at 37 ◦C, 180 rpm. A subculture (1/200)
was incubated for 2 h at 37 ◦C, 180 rpm and later centrifuged at 3000× g during 10 min.
The adhesion of bacteria to human fibronectin (Fn) was assessed in a microtitre plate assay.
Fn (10 µg/mL in 100 µL of PBS) was immobilized onto flat-bottomed microtitre (Nunc
Maxisorp, Thermo Fisher Scientific, Waltham, MA, USA) plates by incubation at 4 ◦C
for 18 h. Wells were washed once and blocked with 200 µL of 3% BSA in PBS at 25 ◦C
for 1 h. Blocked wells were washed with PBS and incubated with 100 µL of bacterial
suspension (1 × 108 CFU/well) at 37 ◦C for 1 h. Non-adherent bacteria were removed by
washing with PBS and adherent bacteria were fixed with 2.5% paraformaldehyde (5 min,
25 ◦C). Fixed bacteria were stained with 100% crystal violet (5 min, 25 ◦C). Two washing
steps with PBS were done before solubilization of crystal violet with 100 µL 7% acetic
acid (5 min, 25 ◦C). The contents of each well were quantified by measurement at Abs 595
nm using a microplate reader (Varioskan, Thermofisher Scientific, Waltham, MA, USA).
Experiments were done in triplicate and repeated three times. Error bars indicate ± 95%
confidence interval.
4.8. Detection of Secreted Hla
Cultures of S. aureus strains were grown overnight in TSB (180 rpm, 37 ◦C) and cul-
tures were normalized to an OD600 nm = 2 before supernatant precipitation [69]. Bacteria
were sedimented by centrifugation (14,600 rpm, 10 min) and the supernatant was incu-
bated and precipitated with trichloroacetic acid (14,600 rpm, 20 min, 4 ◦C). Following
three acetone washes, protein precipitants were resuspended in urea (8 M)-NaOH (1 M)
solution and separated on a 14% SDS-PAGE gel. For each tested strain, the same volume of
protein precipitants solution (40 µL sample and 20 µL loading buffer) was loaded onto each
gel. Hla was detected by Western blotting using a 1:3000 dilution of a rabbit polyclonal
antibody raised against Hla (S7531, Sigma, St. Luis, MO, USA) for 1 h at room temper-
ature. Immunoblots were washed and incubated with horseradish peroxidase-coupled
protein G (1:1000; Invitrogen, Carlsbad, CA, USA) for 1 h at room temperature. Proteins
were detected by using the Opti-4CN detection kit (Bio-Rad, Hercules, CA, USA). Strains
were categorized as producer or non-producer. Each immunoblot had a positive control
that corresponded to protein precipitants from USA300 isolate. NE1354 Tn::hla was also
included as a negative control.
4.9. Invasion Assay
Bacterial strains were selected from the collection (Supplementary Table S2). S. aureus
strains were streaked onto tryptic soy agar (TSA) and incubated for 18 h at 37 ◦C, 180 rpm.
A subculture dilution (1:200) was prepared and cultured for 2.5 h (37 ◦C, 180 rpm). Af-
ter that, bacterial cultures were centrifuged (3000× g, 10 min) and pellet resuspended at
OD600 nM = 0.9. The murine alveolar macrophage (MH-S) cell line (ATCC CRL-2019)
and human epithelial lung cell line A549 (ATCC CCL-185) were cultured according to the
manufacturer’s protocol. The MH-S invasion assay was performed as described previ-
ously [13]. Cells were infected for 30 min (MOI 25:1). Time course analysis of intracellular
S. aureus within MH-S was characterized up to 28 h post-infection. Regarding A549 cell
adhesion (1 h post-infection) and internalization assay (2 h post-infection), an adapted
protocol from [13] was used. Cells were infected for 1 h at MOI 10:1. After 1 h incubation,
wells were washed and cells were incubated for 1 h with gentamycin (200 µg/mL) for one
hour. At interest time points, 1 h and 2 h post-infection, wells were washed in PBS and
lysed with saponin (0.025%). c.f.u were enumerated through serial dilution and plating
onto TSB plates and incubated at 37 ◦C for 24 h.
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4.10. Statistical Analysis
Continuous variables are expressed as mean and standard deviation, and univariate
comparisons were made with Mann–Whitney U test. Multiple groups were compared
by an ordinary one-way ANOVA test. Categorical parameters are expressed as absolute
numbers and percentage and univariate comparisons were performed with Fisher’s exact
test. Differences were considered statistically significant when a p-value was <0.05. For gene
set enrichment analysis (GSEA), multiple testing was accounted for by adjusting for the
numbers of tests performed using a Bonferroni correction. This gave adjusted significance
thresholds of 10−5.2 for genes, 10−4.5 for shared gene ontologies and 10−4.2 for shared
expression pathways. GSEA was performed using R version 3.3. Additional statistical
analysis was performed by using GraphPad Prism version 7.00 (San Diego, CA, USA).
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-665
1/13/2/122/s1, Figure S1: Cytotoxicity and adhesion ability for the 48 clinical strains, each one repre-
sented individually, Table S1: Staphylococcus aureus samples indexed in the BioProject PRJNA673063.
For each sample, the correspondences between the name and the library ID generated in this study
and sequence read archive (SRA) and biosample accession ID generated in the submission to NCBI are
provided; Table S2: Description of clinical strains tested in invasion assays (MH-S and A549 cell lines).
Table S3: Genotype characterization, including MLST and spa type assignment, presence/absence of
selected genes (mecA, fnbA, fnbB, sea, seb, sec, tst, eta, etb, sak, pvl, hla, chp, scn, hlb and hld) and MGE
(numbers of phages and genomic islands) for the 94 clinical strains. ID patient, culture number and
date of isolation are also included. Table S4: Description of variants identified between closely related
(same MLST) isolates from individuals. Variants are classified according to their predicted effect on
the translated protein as synonymous, non-synonymous, frameshift, non-sense or intergenic.
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